TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type
The Oncologist · 05.01.2024 · 29 (1) · 8-14
DOI: 10.1093/oncolo/oyad208 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Oncologist, online erschienen am 18.07.2023. Verfasst von Talal El Zarif und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Hauptthemen laut MEDLINE: Melanoma, Thyroid Neoplasms, Head and Neck Neoplasms, Telomerase. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Background
Telomerase reverse transcriptase (TERT) gene promoter mutations have been explored, as biomarkers of improved survival for patients with cancer receiving immune checkpoint inhibitors. We sought to investigate their prevalence by race and sex across different cancer types to inform patient selection in clinical trials.
Results
In this observational study, 31 925 patients with cancer underwent next-generation sequencing of their tumors with 88% (27 970) patients self-reported being Whites, 7.1% (2273) Asians, and 5.3% (1682) Blacks. Examining the distribution of TERT promoter mutations by race, White patients with melanoma harbored more TERT promoter mutations than Asian and Black patients (OR = 25.83; 95%CI, 6.84-217.42; P < .001). In contrast, Asian patients with head and neck cancer (HNC) harbored more TERT promoter mutations compared to White patients (OR = 2.47; 95%CI, 1.39-4.37; P = .004). In addition, the distribution of TERT promoter mutations differed by sex. Males were enriched for TERT gene promoter mutations compared to females with melanoma (OR = 1.82; 95%CI, 1.53-2.16; P < .001), cancer of unknown primary (OR = 1.96; 95%CI, 1.43-2.69; P < .001), hepatobiliary (OR = 3.89; 95%CI, 2.65-5.69; P < .001), and thyroid cancers (OR = 1.42; 95%CI, 1.10-1.84; P = .0087), while females were more enriched for TERT promoter mutations compared to males for HNC (OR = 0.56; 95%CI, 0.39-0.81; P = .0021).
Conclusions
The prevalence of TERT gene promoter mutations varies among patients with cancer based on race and sex. These findings inform our understanding of cancer biology and can assist in the design of future clinical trials that leverage drugs targeting TERT promoter dependencies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Medicine, Harvard Medical School, Boston, MA, USA.
- Department of Internal Medicine, Yale New Haven Hospital, New Haven, CT, USA.
- Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
- Department of Hematology/Oncology, Yale New Haven Hospital, New Haven, CT, USA.
- Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
ORCID-Profile: Talal El Zarif, Wanling Xie, Toni K Choueiri, Mark Pomerantz
Förderung
- NCATS NIH HHS
Zitieren
APA
El Zarif, T., Machaalani, M., Nawfal, R., Nassar, A. H., Xie, W., Choueiri, T. K., & Pomerantz, M. (2024). TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type. The Oncologist, 29(1), 8-14. https://doi.org/10.1093/oncolo/oyad208
Vancouver
El Zarif T, Machaalani M, Nawfal R, Nassar AH, Xie W, Choueiri TK, et al. TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type. The Oncologist. 2024;29(1):8-14. doi:10.1093/oncolo/oyad208
BibTeX
@article{ElZarif2024,
author = {El Zarif, Talal and Machaalani, Marc and Nawfal, Rashad and Nassar, Amin H and Xie, Wanling and Choueiri, Toni K and Pomerantz, Mark},
title = {TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {1},
pages = {8--14},
doi = {10.1093/oncolo/oyad208}
}
EUVIMED